Global anti-epilepsy drugs market Information, Types of seizures (Generalized seizures and Partial-onset seizures), By Generation (First, second and third) – Forecast to 2022
Market Scenario:
Epilepsy is a group of neurological disorders characterized by seizures manifesting as brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. About 24 million people around the globe suffer from epilepsy with the global epilepsy drugs market reaching USD 3.7 billion in 2015. It is estimated that this market has the potential to reach USD 4.8 billion in 2022 representing a CAGR of 3.79%.
Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/2345
Global Anti-epilepsy Drugs Market – Overview
Epilepsy is a chronic disorder that causes unprovoked and recurrent seizures. Epilepsy is the fourth most common neurological disorder and affects people of all ages. The patients are reported to loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. Increasing prevalence of the epilepsy, rising per capita healthcare expenditure and increasing R&D for the therapeutic procedures of the disease drives the market growth during the forecast period, 2017-2022. According to the World Health Organization in 2017, approximately 50 million people across the globe have epilepsy, making it one of the most common neurological diseases globally. Moreover, it was estimated that nearly 80% of the people with epilepsy live in low- and middle-income countries. Additionally, approval of several late-stage pipeline molecules, advancements in drugs modification and favourable government initiative fuels the market growth. However, side effects related to the therapeutic drugs, increasing generic competition and patent expirations are some of the restrains that for the growth during the forecast period.
The global anti-epilepsy drugs market is growing with the sound pace. According to a recent study report published by the Market Research Future, The global anti-epilepsy drugs market is booming and expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a sound growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).
Global Anti-Epilepsy Drugs Market – Competitive Analysis
Characterized by the presence of several well-established and small players, the global anti-epilepsy drugs market appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott, GlaxoSmithKline plc, Novartis AG, Sanofi, Shire Pharmaceuticals Limited and Cephalon Inc., are some of the prominent players at the forefront of competition in the Global Anti-epilepsy Drugs Market and are profiled in MRFR Analysis.
Browse Complete PRemium Research Report@ https://www.marketresearchfuture.com/reports/anti-epilepsy-drugs-market-2345
Global Anti-epilepsy Drugs Market – Regional Analysis
On the regional backgrounds the Americas leads the global market for anti-epilepsy drugs owing to a well-developed healthcare sector, increasing prevalence of epilepsy and presence of the developed technologies within the region. According to the Centres for Disease Control and Prevention, in 2015, 1.2% of the total U.S. population had active epilepsy. Moreover, it was estimated that the yearly total direct and indirect cost of epilepsy in the U.S. was about USD 15.5 billion. Europe is second in the market due to rising healthcare expenditures, huge patient population and growing healthcare R&D expenses by the government. The Asia Pacific region is the fastest growing region due to the developing economies like India and China which are increasing their healthcare expenditures and have huge patient population. Moreover, favourable government policies within the region fuels the market growth. Middle East and Africa have the least market share, especially due to the presence of poor economies and stringent government policies within the African region.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Email: [email protected]
Global anti-epilepsy drugs market Information, Types of seizures (Generalized seizures and Partial-onset seizures), By Generation (First, second and third) - Forecast to 2022Market HighlightsEpilepsy is a chronic disorder that causes unprovoked and recurrent seizures.
Increasing prevalence of the epilepsy, rising per capita healthcare expenditure and increasing R for the therapeutic procedures of the disease drives the market growth during the forecast period, 2017-2022.Avail a Free Sample@ https://www.marketresearchfuture.com/sample_request/2345According to the World Health Organization in 2017, approximately 50 million people across the globe have epilepsy, making it one of the most common neurological diseases globally.
International players who are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.
The intense competition prevalent in the market dictates the consolidation among marketers.Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.Pfizer Inc. is one of the major players of the global anti-epilepsy drugs market and is headquartered in the U.S.
Such a significant increase in the global sales, enabled the company to invest a huge percentage of their sales into the research and development.
Celgene has done an agreement with Abbott to develop and commercialize the diagnostic tests.In November 2016, Novartis acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders.In August 2017, Sanofi completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, Connecticut in the United States.
The global Epilepsy Drugs Market is anticipated to rise at a staggering CAGR in the forthcoming period.
Epilepsy drugs have pharmacokinetic properties and are administered to children, adults, and adolescents.
Carbamazepine is applicable for focal seizures with strong properties of inducing and enables development of milder tolerance level that could be increased weekly.Epilepsy drugs market is highly driven by rise in cases of stroke, brain tumors, and brain injury.
Antiepileptic drugs are prescribed due to the rising demands for treatment for epilepsy.
Adoption of novel approach by manufacturers for production of therapeutic drugs also contributes to the market growth in the forecast period.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/epilepsy-drugs-market/request-sampleChange in lifestyle and increase in geriatric population with unmet medical needs along with rise in awareness is expected to trigger the market growth in the near future.
However, rise in demand for generic drugs and availability of cheaper substitutes are likely to hinder the market growth in the forecast period.On the basis of generation, the epilepsy drugs market is segmented as first generation epileptic drugs, second generation epileptic drugs, and pipeline drugs.
